Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2018

View Archived Issues

MALAT: unfairly accused of promoting metastasis?

Adaptive and innate immunity is two-way street

LY-3358966 potently inhibits intestinal phosphate absorption in animal models

New compound GDT-01 improves diabetic nephropathy in ZSF1 rats

Bispecific radioimmunoconjugates tested in novel tumor model heterogeneous for HER2 and EGFR

Peptoid-peptide hybrids targeting beta-catenin:TCF interaction show utility in PCa models

Researchers develop the first conditional Fxr2 knockout models of fragile X syndrome

Genetic variants in CD274 increase risk of Fuchs endothelial corneal dystrophy in smokers

L.E.A.F. receives pre-IND feedback from FDA for four anticancer drugs

Clotting protein could be targeted in neurodegeneration

First patient enrolled in phase II study of ANAVEX2-73 for the treatment of PDD

Mirvetuximab soravtansine combined with pembrolizumab is effective in ovarian cancer

Positive long-term data presented from pivotal phase III AMBER study of Symtuza

G2-S16 proves to be safe and effective topical vaginal microbicide against HIV in vivo

Patient enrollment ongoing in phase I study of ADG-106

Preliminary data presented from first-in-human phase I/IIa study of CAN-04

Pilot study evaluates 177Lu-DOTA-EB-TATE in patients with advanced neuroendocrine neoplasms

Scancell updates development of Modi-2 for multiple solid tumors

FDA approves Keytruda with chemotherapy for first-line metastatic squamous NSCLC

InflaRx studies IFX-1 for ANCA-associated vasculitis in phase II

IRLAB offers analysis on phase IIa results of IRL-752 in Parkinson's disease

Aura reports updated results from phase Ib/II trial of AU-011 in choroidal melanoma

Distributed Bio collaborates with H3 Biomedicine to discover novel cancer therapeutics

FDA approves Invokana to reduce risk of CV events in adults with type 2 diabetes and CV disease

Trial results suggest Alzheimer's disease modification with BAN-2401

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...